The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News and events

News and events

News

10/09/2017 Physiogenex will be at the AASLD Liver Meeting 2017

Physiogenex will be attending the AASLD Liver Meeting 2017 in Washington DC, October 20th-24th, 2017. If you wish to know more about our preclinical NASH models to optimize your preclinical drug development program, please contact us to set-up an appointment with Dr. François Briand, Director of Research and Business Development during the Liver meeting. We […]

Read more

06/10/2017 Physiogenex presents the effects of SGLT2 inhibition and glucagon on intestinal cholesterol absorption at ADA 2017, San Diego, USA

Physiogenex has investigated the acute effects of SGLT2 inhibition and glucagon on intestinal cholesterol absorption in the Golden Syrian hamster model. Dr. François Briand, Director of Research and Business Development at Physiogenex, will present the study results during the 77th American Diabetes Association 2017 scientific sessions in San Diego, CA, USA. The oral presentation is scheduled during the oral […]

Read more

06/04/2017 Physiogenex and CLEA Japan Inc. present the benefits of SGLT2 inhibitor dapagliflozin on their 10-week rat model for evaluating drugs targeting Diabetic Nephropathy at ERA-EDTA 2017 congress in Madrid, Spain

Through their partnership put in place in January 2016, Physiogenex and CLEA Japan Inc. have worked thoroughly to set-up and validate a novel rat model for evaluating drugs targeting Diabetic Nephropathy. The Spontaneously Diabetic Torii fatty (SDT fatty) rat, a model of obesity type 2 diabetes distributed by CLEA Japan Inc. since 2012, has been […]

Read more

05/19/2017 Physiogenex and CLEA Japan Inc. present the benefits of SGLT2 inhibitor dapagliflozin on their 10-week rat model for evaluating drugs targeting Diabetic Nephropathy at EDNSG 2017 in Helsinki

Through their partnership put in place in January 2016, Physiogenex and CLEA Japan Inc. have worked thoroughly to set-up and validate a novel rat model for evaluating drugs targeting Diabetic Nephropathy. The Spontaneously Diabetic Torii fatty (SDT fatty) rat, a model of obesity type 2 diabetes distributed by CLEA Japan Inc. since 2012, has been […]

Read more

04/04/2017 Physiogenex and CLEA Japan Inc. present the benefits of SGLT2 inhibitor dapagliflozin on their 10-week rat model for evaluating drugs targeting Diabetic Nephropathy at the World Congress of Nephrology in Mexico

Through their partnership put in place in January 2016, Physiogenex and CLEA Japan Inc. have worked thoroughly to set-up and validate a novel rat model for evaluating drugs targeting Diabetic Nephropathy. The Spontaneously Diabetic Torii fatty (SDT fatty) rat, a model of obesity type 2 diabetes distributed by CLEA Japan Inc. since 2012, has been […]

Read more

03/13/2017 Physiogenex and Vaiomer will present new data dealing with the effects of obeticholic acid in the Diet-Induced NASH (DIN) hamster model at the AASLD ETC on NAFLD, in Washington, DC, USA, March 18-19, 2017.

New data dealing with the effects of obeticholic acid on gut microbiome in the Physiogenex DIN hamster will be disclosed. This unique model to evaluate drugs targeting NASH will be presented by Dr. François Briand, Director of Research and Business Development at Physiogenex, during the poster session on Saturday March the 18th, 2017. If you […]

Read more

02/28/2017 Physiogenex will present the effects of obeticholic acid in its novel Diet-Induced NASH (DIN) hamster model at the Keystone Symposium on Bile Acid Receptors as Signal Integrators in Liver and Metabolism, in Monterey, CA, USA, March 3-7, 2017.

Unlike rats and mice, the DIN hamster has a closer lipid/lipoprotein metabolism as compared to humans. In fact, it replicates the LDL increase and HDL lowering induced by obeticholic acid, as observed in clinical trials. This unique model to evaluate drugs targeting NASH will be presented by Dr. François Briand, Director of Research and Business […]

Read more

12/01/2016 Physiogenex to present its Diet-Induced NASH (DIN) hamster and Unx/salt-supplemented SDT fatty rat models at the World Congress on Insulin Resistance (WCIR) 2016

Physiogenex is proud to present its Diet-Induced NASH (DIN) hamster and Unx/salt-supplemented SDT fatty rat models at the World Congress on Insulin Resistance (WCIR) 2016, in Los Angeles, December 1st-3rd, 2016. These  models will be presented by Dr. François Briand, Director of Research and Business Development, during the poster sessions. If you want to set an […]

Read more

11/18/2016 Physiogenex launches the Diet-Induced NASH (DIN) hamster, a unique model showing the same benefits and side effects of obeticholic acid observed in humans.

Physiogenex now provides the Diet-Induced NASH (DIN) hamster model, a unique model showing the same benefits and side effects (higher LDL-c, lower HDL-c) of obeticholic acid observed in humans. Compare to mouse models, this predictive model is a robust tool to evaluate novel compounds targeting NASH, in comparison with the benchmark obeticholic acid, a FXR agonist. […]

Read more

11/06/2016 Physiogenex and CLEA Japan Inc. to present at the Kidney Week 2016, Nov. 15-20th, 2016, Chicago, IL, USA.

Effects of the SGLT2 inhibitor dapagliflozin in the salt-supplemented/uni-nephrectomized SDT fatty rat, a novel 10-week rat model for evaluating drugs targeting Diabetic Nephropathy. Read the abstract Through their partnership put in place in January 2016, Physiogenex and CLEA Japan Inc. have worked thoroughly to set-up and validate a novel rat model for evaluating drugs targeting […]

Read more

10/29/2016 Physiogenex to present its Diet-Induced NASH (DIN) mouse and hamster models at the liver meeting 2016

Physiogenex is proud to present its Diet-Induced NASH (DIN) mouse and hamster models at the Liver Meeting 2016, in Boston, November 11th-15th, 2016. These NASH models will be presented by Dr. François Briand, Director of Research and Business Development, during oral parallel sessions and late-breaking abstracts poster session as below: -Parallel 20 (Steatohepatitis:  Experimental I): […]

Read more

Events

02/07/2017 Physiogenex to present its 3-week NASH screening mouse model and the Diet-Induced NASH hamster model at the APASL 2017 in Shanghai.

Physiogenex will present its 3-week NASH screening model and the Diet-Induced NASH (DIN) hamster model during the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL), February 15-19, 2017 in Shanghai, China. These models will be presented by Dr. François Briand, Director of Research and Business Development at Physiogenex, during oral abstracts […]

Read more